Investor Relations https://validator.w3.org/feed/docs/rss2.html Pulmatrix and Eos merge to advance gerotherapeutics Investor Relations Media Center PrintBio Contributes 3D Bioprinting Expertise to ARPA-H PRINT Program for Kidney Bioprinting PrintBio Introduces DynaFlex™ Programmable Surgical Mesh (PSM) at 2025 American Hernia Society Meeting PrintBio Introduces DynaFlex™ at the American Society of Plastic Surgery annual meeting Events & Presentations Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan DEPRECATED – Events and Presentations PrintBio Receives FDA Clearance for 3DMatrix™, the First 3D-Printed Resorbable Surgical Mesh  Human Ear Reconstruction Using 3D-Bioprinted Living Tissue Implant in a First-in-Human Clinical Trial PrintBio Receives FDA Clearance for 3DMatrix DynaFlex™, Adding Uniflex™ Technology to 3DMatrix™, the First 3D-Printed Resorbable Surgical Mesh Approved Less than One Year Ago PrintBio Reorganizes and Expands Leadership Team with Key Commercial and Market Development Appointments PrintBio Introduces DynaFlex™ Programmable Surgical Mesh (PSM) at American Hernia Society Meeting 2025 Doctors Transplant Ear of Human Cells, Made by 3-D Printer 3DBio Therapeutics Receives FDA Rare Pediatric Disease Designation for AuriNovo™ for Ear Reconstruction in Microtia Patients 3DBio Therapeutics Receives Orphan Drug Designation for AuriNovo™ for Ear Reconstruction in Microtia Patients Sample Page Pulmatrix picked for reverse merger with anti-aging biotech weeks after Cullgen deal collapses Protected: Media Room Financials and Filings Brent Saunders Appointed as Advisory Board Chairman